On July 25, 2019, Health Canada released an updated version of the Guidance Document: The Management of Drug Submissions and Applications. The updates follow from an earlier consultation and reflect updated processes and procedures related to filing a submission or application to Health Canada. These changes include a broad reorganization of information, an added section on classification of a therapeutic product (e.g., as a drug, biologic, a medical device or a combination product), and modified times to respond to a clarification request during a scientific review, which are based on the type and performance standard of the submission/application.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada consultation on two draft guidance documents on terms and conditions for human and veterinary drugs and drug submissions based on promising evidence of clinical efficacy
As previously reported, in December 2024, Health Canada published its agile licensing amendments to the Food and Drug Regulations.Read More -
2025 highlights in Canadian life sciences IP and regulatory law
In 2025, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
Proposed Ministerial Reliance Order would allow Health Canada to rely on decisions of foreign trusted regulators
On December 19, 2025, the Minister of Health announced the launch of consultations on two key regulatory initiatives referenced in Health Canada’s Red Tape Review report: (i) the Ministerial Reliance ...Read More
